BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK, Tu YX. Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine. Sci Rep. 2018;8:1621. [PMID: 29374219 DOI: 10.1038/s41598-018-20004-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu B, Wu S, Ma J, Yan S, Xiao Z, Wan L, Zhang F, Shang M, Mao A. lncRNA GAS5 Reverses EMT and Tumor Stem Cell-Mediated Gemcitabine Resistance and Metastasis by Targeting miR-221/SOCS3 in Pancreatic Cancer. Mol Ther Nucleic Acids 2018;13:472-82. [PMID: 30388621 DOI: 10.1016/j.omtn.2018.09.026] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
2 Gupta S, Kumar A, Tejavath KK. Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review. Mol Biol Rep 2021;48:2945-56. [PMID: 33796989 DOI: 10.1007/s11033-021-06318-9] [Reference Citation Analysis]
3 Clemente-Periván SI, Gómez-Gómez Y, Leyva-Vázquez MA, Lagunas-Martínez A, Organista-Nava J, Illades-Aguiar B. Role of Oct3/4 in Cervical Cancer Tumorigenesis. Front Oncol 2020;10:247. [PMID: 32219062 DOI: 10.3389/fonc.2020.00247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zhao Q, Ji K, Wang T, Li G, Lu W, Ji J. Effect of the Histone Deacetylases Inhibitors on the Differentiation of Stem Cells in Bone Damage Repairing and Regeneration. Curr Stem Cell Res Ther 2020;15:24-31. [PMID: 31486757 DOI: 10.2174/1574888X14666190905155516] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Juiz NA, Iovanna J, Dusetti N. Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome. Front Oncol 2019;9:246. [PMID: 31024848 DOI: 10.3389/fonc.2019.00246] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
7 Mastoraki A, Schizas D, Vlachou P, Melissaridou NM, Charalampakis N, Fioretzaki R, Kole C, Savvidou O, Vassiliu P, Pikoulis E. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma. Mol Diagn Ther 2020;24:557-69. [PMID: 32696211 DOI: 10.1007/s40291-020-00487-2] [Reference Citation Analysis]
8 Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer 2021;21:632. [PMID: 34049503 DOI: 10.1186/s12885-021-08388-1] [Reference Citation Analysis]
9 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
10 Nguyen A, Dzulko M, Murr J, Yen Y, Schneider G, Krämer OH. Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Cells 2021;10:2520. [PMID: 34685500 DOI: 10.3390/cells10102520] [Reference Citation Analysis]
11 Layeghi-Ghalehsoukhteh S, Pal Choudhuri S, Ocal O, Zolghadri Y, Pashkov V, Niederstrasser H, Posner BA, Kantheti HS, Azevedo-Pouly AC, Huang H, Girard L, MacDonald RJ, Brekken RA, Wilkie TM. Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Sci Rep 2020;10:20662. [PMID: 33244070 DOI: 10.1038/s41598-020-77373-8] [Reference Citation Analysis]
12 Miao H, Chen X, Luan Y. Small Molecular Gemcitabine Prodrugs for Cancer Therapy. Curr Med Chem 2020;27:5562-82. [PMID: 31419928 DOI: 10.2174/0929867326666190816230650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Santos SM, Icyuz M, Pound I, William D, Guo J, McKinney BA, Niederweis M, Rodgers J, Hartman JL IV. A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity. Genes (Basel) 2019;10:E770. [PMID: 31575041 DOI: 10.3390/genes10100770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Kim GH, Choi SY, Oh TI, Kan SY, Kang H, Lee S, Oh T, Ko HM, Lim JH. IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells. Int J Mol Sci 2019;20:E2679. [PMID: 31151327 DOI: 10.3390/ijms20112679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Kaneta Y, Sato T, Hikiba Y, Sugimori M, Sue S, Kaneko H, Irie K, Sasaki T, Kondo M, Chuma M, Shibata W, Maeda S. Loss of Pancreatic E-Cadherin Causes Pancreatitis-Like Changes and Contributes to Carcinogenesis. Cell Mol Gastroenterol Hepatol 2020;9:105-19. [PMID: 31526907 DOI: 10.1016/j.jcmgh.2019.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 Webber LP, Yujra VQ, Vargas PA, Martins MD, Squarize CH, Castilho RM. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence. Cancer Lett 2019;461:10-20. [PMID: 31265875 DOI: 10.1016/j.canlet.2019.06.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
17 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
18 Wang X. Stem cells in tissues, organoids, and cancers. Cell Mol Life Sci. 2019;76:4043-4070. [PMID: 31317205 DOI: 10.1007/s00018-019-03199-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Roca MS, Di Gennaro E, Budillon A. Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors. J Clin Med 2019;8:E912. [PMID: 31247937 DOI: 10.3390/jcm8070912] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
20 Xu L, Xing Q, Huang T, Zhou J, Liu T, Cui Y, Cheng T, Wang Y, Zhou X, Yang B, Yang GL, Zhang J, Zang X, Ma S, Guan F. HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway. Front Cell Neurosci 2018;12:498. [PMID: 30662396 DOI: 10.3389/fncel.2018.00498] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
21 Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem 2021;226:113825. [PMID: 34562854 DOI: 10.1016/j.ejmech.2021.113825] [Reference Citation Analysis]
22 Perusina Lanfranca M, Thompson JK, Bednar F, Halbrook C, Lyssiotis C, Levi B, Frankel TL. Metabolism and epigenetics of pancreatic cancer stem cells. Semin Cancer Biol 2019;57:19-26. [PMID: 30273655 DOI: 10.1016/j.semcancer.2018.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
23 Stampone E, Caldarelli I, Zullo A, Bencivenga D, Mancini FP, Della Ragione F, Borriello A. Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases. Int J Mol Sci 2018;19:E1055. [PMID: 29614816 DOI: 10.3390/ijms19041055] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
24 Fatma H, Siddique HR, Maurya SK. The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers. Epigenomics 2021;13:1885-900. [PMID: 34693722 DOI: 10.2217/epi-2021-0228] [Reference Citation Analysis]